Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aclerastide - Derma Sciences

Next Previous
Drug Profile

Aclerastide - Derma Sciences

Alternative Names: [Nle3]-Angiotensin II (1-7); DSC-127; NorLeu3-A(1-7); USB 005

Latest Information Update: 28 Aug 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Southern California
  • Developer Derma Sciences; United States Department of Defense; US Biotest Inc
  • Class Angiotensins; Hexanoic acids; Peptides; Skin disorder therapies
  • Mechanism of Action Angiotensin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Diabetic foot ulcer

Highest Development Phases

  • Suspended Radiation-induced skin damage; Scars
  • No development reported Wounds
  • Discontinued Diabetic foot ulcer

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for phase-I development in Wounds(In volunteers) in USA (Ophthalmic, Liquid)
  • 25 Jul 2018 Phase-I clinical trials in Wounds (In volunteers) in USA (Ophthalmic) (NCT03615196)
  • 12 Nov 2015 Discontinued - Phase-III for Diabetic foot ulcer in Canada (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top